GS
TEVA icon

GTS Securities’s Teva Pharmaceuticals TEVA Stock Holding History

GTS Securities’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-46,218
Closed -$1.39M – 1854
2026
Q1 		$1.39M Buy
+46,218
New +$1.49M 0.05% 281
2025
Q4 		– Sell
-104,860
Closed -$2.12M – 1780
2025
Q3 		$2.12M Buy
104,860
+64,116
+157% +$1.13M 0.08% 193
2025
Q2 		$683K Buy
40,744
+23,585
+137% +$381K 0.03% 522
2025
Q1 		$264K Buy
+17,159
New +$307K 0.01% 1014
2024
Q4 		– Sell
-379,668
Closed -$6.84M – 3814
2024
Q3 		$6.84M Buy
379,668
+988
+0.3% +$17.3K 0.01% 701
2024
Q2 		$6.15M Sell
378,680
-647,180
-63% -$9.97M 0.01% 736
2024
Q1 		$14.5M Buy
1,025,860
+276,106
+37% +$3.48M 0.03% 359
2023
Q4 		$7.83M Buy
749,754
+16,409
+2% +$153K 0.01% 735
2023
Q3 		$7.48M Sell
733,345
-19,364
-3% -$180K 0.01% 724
2023
Q2 		$5.67M Buy
+752,709
New +$6.1M 0.18% 117

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

GTS Securities's TEVA Position: Q2 2026 in Review

GTS Securities sold out of Teva Pharmaceuticals (TEVA) in Q2 2026, closing a stake of 46,218 shares — an estimated $1.39M sold.

GTS Securities first reported a position in TEVA in Q2 2023 and held it in 10 quarters. The position peaked at $14.5M in Q1 2024. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • GTS Securities reported no remaining Teva Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • GTS Securities sold 46,218 Teva Pharmaceuticals shares in Q2 2026, an estimated $1.39M.
  • GTS Securities first reported a position in Teva Pharmaceuticals in Q2 2023 and held it in 10 quarters.
  • GTS Securities's Teva Pharmaceuticals position peaked at $14.5M in Q1 2024.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.